# Vorinostat, Azacitidine, and Gemtuzumab Ozogamicin for Older Patients With Relapsed or Refractory AML

> **NCT00895934** · PHASE1,PHASE2 · COMPLETED · sponsor: **National Cancer Institute (NCI)** · enrollment: 52 (actual)

## Conditions studied

- Adult Acute Megakaryoblastic Leukemia (M7)
- Adult Acute Minimally Differentiated Myeloid Leukemia (M0)
- Adult Acute Monoblastic Leukemia (M5a)
- Adult Acute Monocytic Leukemia (M5b)
- Adult Acute Myeloblastic Leukemia With Maturation (M2)
- Adult Acute Myeloblastic Leukemia Without Maturation (M1)
- Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities
- Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)
- Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)
- Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)
- Adult Acute Myelomonocytic Leukemia (M4)
- Adult Erythroleukemia (M6a)
- Adult Pure Erythroid Leukemia (M6b)
- Recurrent Adult Acute Myeloid Leukemia

## Interventions

- **DRUG:** vorinostat
- **DRUG:** gemtuzumab ozogamicin
- **DRUG:** azacitidine

## Key facts

- **NCT ID:** NCT00895934
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-05
- **Primary completion:** 2013-07
- **Final completion:** 2013-09
- **Target enrollment:** 52 (ACTUAL)
- **Last updated:** 2019-05-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00895934

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00895934, "Vorinostat, Azacitidine, and Gemtuzumab Ozogamicin for Older Patients With Relapsed or Refractory AML". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT00895934. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*